Pharmacokintic optimisation of dopamine receptor agonist therapy for Parkinson's disease

CNS Drugs

Volumn 14, Issue 6, 2000, Pages 439-455

  Contin, M ^a   Riva, R ^a   Albani, F ^a   Baruzzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE;

AUTONOMIC NERVOUS SYSTEM; COGNITION; DRUG BIOAVAILABILITY; DRUG FORMULATION; FIRST PASS EFFECT; HUMAN; MOTOR ACTIVITY; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0034525742     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014060-00003     Document Type: Review

References (147)

1. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications
2. Therapeutic strategies in Parkinson's disease
3. Parkinson's disease
4. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
5. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
6. Pathogenesis of dyskinesias in Parkinson's disease
7. L-3-4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydoparmine-treated rats: Differential effects of monoamine oxidase A and B inhibitors
8. A hypothesis on the pathophysiologic mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
9. Episodic unresponsiveness to single doses of 1-dopa in parkinsonian fluctuators
10. Treatment of early Parkinson's disease: Are complicated strategies justified?
11. Dopamine agonists: What is the place of the newer compounds in the treatment of Parkinson's disease?
12. The role of dopamine agonists in early Parkinson's disease
13. Antiparkinsonian dopamine agonists: A review of the pharmacokinetics and neuropharmacology in animals and humans
14. Should treatment of Parkinson's disease be started with a dopamine agonist?
15. Parkinson's disease management: Towards a new paradigm
16. Dopamine receptors in the basal ganglia: Relevance to Parkinson's disease
17. Effects of bromocriptine on central dopaminergic receptors
18. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism
19. Pergolide: A dopamine agonist at both D1 and D2 receptors
20. Parkinson's disease: Pathological mechanisms and actions of piribedil
21. Dopamine D1 receptor agonists. The way forward for the treatment of Parkinson's disease?
22. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study
23. Dopamine D3 receptors. Relevance for the drug treatment of Parkinson's disease
24. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists
25. Dopamine-receptor families and the treatment of Parkinson's disease
26. Differential effects of D1 and D2 agonists in MPTP-treated primates: Functional implications for Parkinson's disease
27. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys
28. Clinical classification of dopaminergic effects in parkinsonism
29. Low-dose bromocriptine in the early phases of Parkinson's disease
30. Deterioration in parkinsonism with low-close pergolide
31. Low and high dose bromocriptine have different effects on striatal dopamine release: An in vivo study
32. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans
33. Comparative review of dopamine receptor agonists in Parkinson's disease
34. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease
35. Bromocriptine-induced pleuropulmonary fibrosis
36. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide
37. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide
38. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline
39. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease
40. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism
41. The pharmacokinetics of bromocriptine in man
42. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation
43. Physiologic disposition of pergolide
44. Pergolide. A review of its pharmacology and therapeutic use in Farkinson's disease
45. Disposition of oral lisuride in Parkinson's disease
46. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level
47. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man
48. Metabolism and kinetics of ET 495 (piribedil) in man and rats
49. Piribédil: Nouvelles donees de pharmacocinétique et de métabolisme chez l'homme
50. Activity and acceptability of piribedil in Parkinson's disease: A multicentre study
51. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers
52. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers
53. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers
54. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man
55. Disposition of ropinirole in animals and man
56. Pharmacokinetic data for ropinirole
57. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
58. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease
59. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease
60. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease
61. Linear pharmacokinetics of ropinirole in patients with Parkinson's disease
62. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers
63. Influence of renal impairment and hemodialysis on pramipexole pharmacokinetics
64. Influence of age and gender on pramipexole pharmacokinetics
65. Ropinirole and pramipexole, the new agonists
66. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma
67. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine
68. Therapeutic applications of bromocriptine in endocrine and neurological disease
69. Fate and disposition of bromocriptine in animals and man. I: Structure elucidation of the metabolites
70. Pharmacokinetic drug interactions with antimicrobial agents
71. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
72. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
73. Lack of pharmacokinetic influence on levodopa by bromocriptine
74. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease
75. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease
76. Levodopa pharmacokinetics and dopamine agonist cotherapy [abstract]
77. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease
78. Bromocriptine in Parkinsonism: Long-term treatment, dose response, and comparison with levodopa
79. Bromocriptine: Low-dose therapy in Parkinson disease
80. Low-dose bromocriptine therapy in Parkinson's disease
81. Domperidone and Parkinson's disease
82. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease
83. Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects
84. Antiparkinsonian agents. Clinically significant drug interactions and adverse effects, and their management
85. Antiparkinsonian agents. Drug interactions of clinical significance
86. Practical guidelines for the drug treatment of Parkinson's disease
87. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias
88. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa
89. Lisuride in Parkinsonism
90. Pharmacokinetic optimisation in the treatment of Parkinson's disease
91. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection
92. Cabergoline. A review of its efficacy in the treatment of Parkinson's disease
93. Cabergoline in Parkinson's disease
94. Is a second administration of cabergoline useful? Results of a double-blind, randomized multicenter study
95. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole
96. Ropinirole without levodopa in Parkinson's disease
97. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease
98. Influence of probenecid and cimetidine on pramipexole pharmacokinetics
99. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?
100. An overnight switch to ropinirole therapy in patients with Parkinson's disease
101. The replacement of pergolide with ropinirole: A dose substitution study
102. Acute versus gradual pramipexole to ropinirole switch
103. Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations
104. A 'combined' levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine
105. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline
106. Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations
107. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
108. Control of on/off phenomenon by continuous intravenous infusion of levodopa
109. Duodenal and gastric delivery of levodopa in Parkinsonism
110. Perioperative problems in Parkinson's disease and their management: Apomorphine with rectal domperidone
111. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease
112. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson's disease
113. Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease
114. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
115. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism
116. Transdermal, dopaminergic stimulation in Parkinson's disease
117. The spectrum of levodopa-related fluctuations in Parkinson's disease
118. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
119. Apomorphine in patients with Parkinson's disease
120. Absorption of apomorphine by various routes in Parkinsonism
121. O-methylation of apomorphine and the metabolic prolongation of apomorphine-induced stereotyped behaviour
122. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease
123. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease
124. Peripheral pharmacokinetics of apomorphine in humans
125. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease
126. Subcutaneous apomorphine in the treatment of Parkinson's disease
127. Pharmacokinetics of apomorphine in parkinsonian patients
128. Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application
129. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study
130. Intranasal apomorphine: A new treatment in Parkinson's disease
131. Intranasal apomorphine in parkinsonian on-off fluctuations
132. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations
133. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease
134. Sublingual apomorphine in Parkinson's disease: A clinical and pharmacokinetic study
135. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease
136. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories
137. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes
138. Subcutaneous apomorphine in late stage Parkinson's disease: A long term follow up
139. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
140. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease
141. The role of EDTA in provoking allergic reactions of subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study
142. Apomorphine does not modify levodopa pharmacokinetics
143. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations
144. Adouble-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-state in Parkinson's disease
145. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
146. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where and what
147. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives